AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Notch homolog 2 N-terminal-like protein C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P0DPK4

UPID:

NT2NC_HUMAN

Alternative names:

-

Alternative UPACC:

P0DPK4; A0A494C1K9

Background:

Notch homolog 2 N-terminal-like protein C plays a pivotal role in brain development by regulating the Notch signaling pathway. It promotes neural progenitor proliferation, contributing to the evolutionary expansion of the brain neocortex. This protein enhances Notch signaling both directly, through interaction with NOTCH2, and indirectly, by inhibiting cis DLL1-NOTCH2 interactions, thus delaying neuronal differentiation.

Therapeutic significance:

Linked to diseases such as Neuronal intranuclear inclusion disease, hereditary essential tremor 6, and oculopharyngodistal myopathy 3, understanding the role of Notch homolog 2 N-terminal-like protein C could open doors to potential therapeutic strategies. Its involvement in these conditions highlights its importance in neural function and disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.